PBLS Parabilis Medicines, Inc. Insider Trading

Director Alan Sebulsky purchases 17,500 shares across 3 transactions for $473,528.54, increasing stake by 140% to 30,000 shares.

Alan Sebulsky, a Director at Parabilis Medicines, executed 3 separate purchases totaling 17,500 shares for $473,528.54 between June 12–15, 2026, at prices ranging from $26.00 to $27.67 (blended average $27.06). The aggregate purchase increased his holdings from 12,500 shares to 30,000 shares, representing a 140% increase in position size. The purchases occurred within days of the company's recent IPO listing (5 trading days old as of the filing date), and the current market price of $26.59 sits just below the blended transaction price of $27.06. The concentrated and substantial nature of this multi-transaction purchase—nearly tripling director holdings over a compressed timeframe—is noteworthy for a newly public company where director positioning during the initial post-listing period may signal conviction or reflect capital allocation strategy at a critical juncture in the company's public market history.

RA Capital Management director acquired 21,188,750 shares ($423.8M) at $20.00 in PIPE placement at PBLS IPO.

RA Capital Management, LP, acting as director of Parabilis Medicines, completed 2 separate share purchases totaling 21,188,750 shares (21.19M shares) for $423,775,000.00 ($423.8M) at $20.00 per share on June 11, 2026. This transaction is a private placement (PIPE) allocation tied to PBLS's recent IPO, not a discretionary open-market purchase, so it reflects allocation participation rather than a conviction-driven buying signal. The company is trading at $25.01 as of June 15, 2026—four trading days after listing—representing modest outperformance versus the $20.00 subscription price. RA Capital's post-transaction non-derivative holdings of 2,648,278 shares reflect only a portion of the investor's total position; earlier preferred stock holdings are no longer reflected post-transaction, indicating conversion or redemption as part of the IPO transition.

Director Alan Sebulsky buys 12,500 shares of PBLS at $20.00 for $250,000.00; stock now at $25.01 after 4-day listing

Alan Sebulsky, a Director, purchased 12,500 shares at $20.00 on 2026-06-11, establishing his first recorded holding in Parabilis Medicines at a total value of $250,000.00. The stock has traded up to $25.01 as of 2026-06-15, four trading days after listing. This initial director investment in a newly public company during the earliest price formation phase may reflect confidence in the company's IPO positioning, though the recent listing status means historical trading patterns are not yet established.